Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares Outstanding
Ratios

BioCorRx (BICX) Shares Outstanding (2016 - 2025)

BioCorRx (BICX) has disclosed Shares Outstanding for 16 consecutive years, with $24.5 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 84.14% to $24.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.5 million through Dec 2025, up 84.14% year-over-year, with the annual reading at $24.5 million for FY2025, 84.14% up from the prior year.
  • Shares Outstanding hit $24.5 million in Q4 2025 for BioCorRx, up from $20.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $24.5 million in Q4 2025 to a low of $80000.0 in Q2 2021.
  • Historically, Shares Outstanding has averaged $6.2 million across 5 years, with a median of $3.4 million in 2021.
  • Biggest five-year swings in Shares Outstanding: plummeted 98.14% in 2024 and later skyrocketed 12517.52% in 2025.
  • Year by year, Shares Outstanding stood at $6.7 million in 2021, then rose by 15.22% to $7.7 million in 2022, then increased by 12.38% to $8.7 million in 2023, then skyrocketed by 53.32% to $13.3 million in 2024, then soared by 84.14% to $24.5 million in 2025.
  • Business Quant data shows Shares Outstanding for BICX at $24.5 million in Q4 2025, $20.2 million in Q3 2025, and $16.9 million in Q1 2025.